Neuvivo

Palo Alto, United States

Neuvivo is a late clinical-stage biopharmaceutical company developing a new ALS treatment.

$11.0M raised

Jun 2023

Venture - Series Unknown

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Neuvivo raised?

Neuvivo has raised $11.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in June 2023.

Who are Neuvivo's investors?

Neuvivo's investors include Primestreet Group.

Where is Neuvivo headquartered?

Neuvivo is headquartered in Palo Alto, United States.

What does Neuvivo do?

Neuvivo is a late clinical-stage biopharmaceutical company developing a new ALS treatment.

What stage is Neuvivo at?

Neuvivo is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 15, 2023.

MLA

"Neuvivo — Funding & Investors." VCBacked, June 15, 2023, https://www.vcbacked.co/company/neuvivo. Accessed July 3, 2026.

APA

VCBacked. (2023). Neuvivo — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/neuvivo

Wikipedia (cite web)

{{cite web |title=Neuvivo — Funding & Investors |url=https://www.vcbacked.co/company/neuvivo |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 15, 2023.